CHM chimeric therapeutics limited

CDH17 Phase 1/2 trial, page-10

  1. 14,263 Posts.
    lightbulb Created with Sketch. 4257
    ASX said not worthy of a " standalone " - anns but I think it should be. Anyway, here is the official statement by Dr Bec:

    Thank you for your enquiry.

    The disclosure you refer to was determined following consultation with our professional advisers and the ASX.

    The information published on LinkedIn was not considered to be sufficiently ‘market sensitive’ to justify being released on ASX as a standalone announcement. The Company was reminded of provisions in the ASX Listing Rule Guidance Notes deterring companies from lodging non-market sensitive announcements on ASX.

    As the information was determined not to be market sensitive from an ASX perspective, and unable to be released on ASX in a standalone announcement, the Company shared the information on social media and a standard media release.

    Thank you for your interest and ongoing support of Chimeric.

    Regards


 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.3¢
Change
-0.001(25.0%)
Mkt cap ! $9.747M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $11.33K 3.775M

Buyers (Bids)

No. Vol. Price($)
75 71644408 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 87927011 26
View Market Depth
Last trade - 14.48pm 31/07/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.